Practice Update | Onology

GIVE YOUR PATIENTS A KEY FOR FIRST-LINE TREATMENT OF METASTATIC MELANOMA

KEYTRUDA is indicated as monotherapy for the treatment of unresectable or metastatic melanoma in adults. ¹

PBS Information: Authority required (STREAMLINED) for treatment of metastatic melanoma. Refer to PBS Schedule for full authority information.

Before prescribing, please review the Product Information. Product Information is available at www.msdinfo.com.au/keytrudapi

Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. ONCO-1130195-0277. First issued June 2017. MSDONC1065.